Meta‑Analysis: S. boulardii Shortens Duration of Acute Diarrhoea in Children
Dr. Kumar’s Take
This meta‑analysis gives strong validation to what has been long understood in clinical practice: using S. boulardii for acute infectious diarrhoea in children cuts down the misery. Fewer loose stools and shorter illness duration. Though not perfect, it’s strong enough evidence that probiotic adjunct therapy should be considered in standard protocols for childhood gastroenteritis.
Key Takeaways
- Based on 5 randomized controlled trials with 619 children suffering acute infectious diarrhoea.
- On average, S. boulardii shortens diarrhoea duration by about 1.1 days compared to placebo or control.
- Greater proportion of children had resolved diarrhoea by days 3, 6, and 7 in the S. boulardii groups.
- Risk of diarrhoea lasting more than 7 days significantly reduced; Number Needed to Treat (NNT) about 5 in that subgroup.
- Safety: no major adverse effects reported; tolerability was good.
Actionable Tip
For children with acute infectious diarrhoea, start Saccharomyces boulardii (roughly 250 mg twice daily, depending on age and formulation) alongside standard care like rehydration. Expect illness duration shortened by about one day if used early.